Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation
Clinical trial NCT06414915 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06414915
- Sponsor
- National Cancer Center, China
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-01
- Primary completion
- 2026-06-01
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.